Open Federal Grants · National Institutes of Health
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
National Institutes of Health · Opportunity PAR-25-226 · Award amount: see the official listing
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-b
Eligibility text quoted from the official Grants.gov listing.
About This Opportunity
The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD). Candidate interventions evaluated through this program, which can include small molecules or biologics for example, must engage non-amyloid/non-tau mecha …
Description from the official Grants.gov listing — read the complete notice, including any updates, on Grants.gov before applying.
More Open Grants From NIH
Browse Open Grants
By who can apply:
By agency:
By closing month:
Every grant listed here comes from Grants.gov, the official U.S. government database. Award amounts and deadlines can change — verify the details on the official listing before you apply. GrantRound is not affiliated with the U.S. government.